MR Imaging And MR Spectroscopic Imaging Of Prostate Cancer Prior To Radical Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study
- Compare the accuracy of MRI vs MRI combined with magnetic resonance spectroscopic
imaging (MRSI) for the localization of prostate cancer prior to radical prostatectomy
in patients with stage I or II adenocarcinoma of the prostate.
- Compare the incremental benefit of these tests on diagnostic accuracy in these
- Compare the incremental benefit of MRSI for interobserver agreement vs MRI alone in the
localization of prostate cancer in these patients.
- Compare the accuracy of combined MRSI with that of other available information on tumor
extent derived from digital rectal exam, PSA level, Gleason score, and Partin nomogram
in these patients.
OUTLINE: This is a multicenter study.
At least 6 weeks after biopsy, patients undergo MRI and magnetic resonance spectroscopic
imaging (MRSI) over approximately 1 hour. Within 6 months of MRI/MRSI, patients undergo
PROJECTED ACCRUAL: A total of 134 patients will be accrued for this study within 7 months.
Masking: Open Label, Primary Purpose: Diagnostic
Jeffrey Weinreb, MD
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|Yale Comprehensive Cancer Center||New Haven, Connecticut 06520-8028|
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|
|UCSF Comprehensive Cancer Center||San Francisco, California 94115|
|M.D. Anderson Cancer Center at University of Texas||Houston, Texas 77030|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|